Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 205

1.

Plasma proteomics identifies a 'chemokine storm' in idiopathic multicentric Castleman disease.

Pierson SK, Stonestrom AJ, Shilling D, Ruth J, Nabel CS, Singh A, Ren Y, Stone K, Li H, van Rhee F, Fajgenbaum DC.

Am J Hematol. 2018 Apr 20. doi: 10.1002/ajh.25123. [Epub ahead of print]

PMID:
29675946
2.

Kinase domain activation through gene rearrangement in multiple myeloma.

Morgan GJ, He J, Tytarenko R, Patel P, Stephens OW, Zhong S, Deshpande S, Bauer M, Weinhold N, Schinke C, Rasche L, Bailey M, Ali S, Ross J, Miller VA, Stephens P, Thanendrarajan S, Zangari M, van Rhee F, Mughal T, Davies FE, Walker BA.

Leukemia. 2018 Mar 23. doi: 10.1038/s41375-018-0108-y. [Epub ahead of print]

PMID:
29654269
3.

Daratumumab for POEMS Syndrome.

Khan M, Stone K, van Rhee F.

Mayo Clin Proc. 2018 Apr;93(4):542-544. doi: 10.1016/j.mayocp.2018.02.001. No abstract available.

PMID:
29622102
4.

Treatment to suppression of focal lesions on positron emission tomography-computed tomography is a therapeutic goal in newly diagnosed multiple myeloma.

Davies FE, Rosenthal A, Rasche L, Petty NM, McDonald JE, Ntambi JA, Steward DM, Panozzo SB, van Rhee F, Zangari M, Schinke CD, Thanendrarajan S, Walker B, Weinhold N, Barlogie B, Hoering A, Morgan GJ.

Haematologica. 2018 Mar 22. pii: haematol.2017.177139. doi: 10.3324/haematol.2017.177139. [Epub ahead of print]

5.

The Pattern of Mesenchymal Stem Cell Expression Is an Independent Marker of Outcome in Multiple Myeloma.

Schinke C, Qu P, Mehdi SJ, Hoering A, Epstein J, Johnson SK, van Rhee F, Zangari M, Thanendrarajan S, Barlogie B, Davies FE, Yaccoby S, Morgan GJ.

Clin Cancer Res. 2018 Mar 21. doi: 10.1158/1078-0432.CCR-17-2627. [Epub ahead of print]

PMID:
29563136
6.

Myeloid transformation of plasma cell myeloma: molecular evidence of clonal evolution revealed by next generation sequencing.

Gralewski JH, Post GR, van Rhee F, Yuan Y.

Diagn Pathol. 2018 Feb 20;13(1):15. doi: 10.1186/s13000-018-0692-1.

7.

Castleman Disease.

van Rhee F, Munshi NC.

Hematol Oncol Clin North Am. 2018 Feb;32(1):xiii-xiv. doi: 10.1016/j.hoc.2017.10.001. No abstract available.

PMID:
29157623
8.

Treatment of Idiopathic Castleman Disease.

van Rhee F, Greenway A, Stone K.

Hematol Oncol Clin North Am. 2018 Feb;32(1):89-106. doi: 10.1016/j.hoc.2017.09.008. Review.

9.

Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing.

Rasche L, Chavan SS, Stephens OW, Patel PH, Tytarenko R, Ashby C, Bauer M, Stein C, Deshpande S, Wardell C, Buzder T, Molnar G, Zangari M, van Rhee F, Thanendrarajan S, Schinke C, Epstein J, Davies FE, Walker BA, Meissner T, Barlogie B, Morgan GJ, Weinhold N.

Nat Commun. 2017 Aug 16;8(1):268. doi: 10.1038/s41467-017-00296-y.

10.

The level of deletion 17p and bi-allelic inactivation of TP53 has a significant impact on clinical outcome in multiple myeloma.

Thanendrarajan S, Tian E, Qu P, Mathur P, Schinke C, van Rhee F, Zangari M, Rasche L, Weinhold N, Alapat D, Bellamy W, Ashby C, Mattox S, Epstein J, Yaccoby S, Barlogie B, Hoering A, Bauer M, Walker BA, Davies FE, Morgan GJ.

Haematologica. 2017 Sep;102(9):e364-e367. doi: 10.3324/haematol.2017.168872. Epub 2017 May 26. No abstract available.

11.

The prognostic value of the depth of response in multiple myeloma depends on the time of assessment, risk status and molecular subtype.

Schinke C, Hoering A, Wang H, Carlton V, Thanandrarajan S, Deshpande S, Patel P, Molnar G, Susanibar S, Mohan M, Mathur P, Radhakrishnan M, Hoque S, Jo Kamimoto J, Grazziutti M, van Rhee F, Zangari M, Insuasti-Beltran G, Alapat D, Post G, Yaccoby S, Epstein J, Rasche L, Johnson S, Moorhead M, Willis T, Barlogie B, Walker B, Weinhold N, Davies FE, Morgan GJ.

Haematologica. 2017 Aug;102(8):e313-e316. doi: 10.3324/haematol.2017.165217. Epub 2017 May 18. No abstract available.

12.

Low expression of hexokinase-2 is associated with false-negative FDG-positron emission tomography in multiple myeloma.

Rasche L, Angtuaco E, McDonald JE, Buros A, Stein C, Pawlyn C, Thanendrarajan S, Schinke C, Samant R, Yaccoby S, Walker BA, Epstein J, Zangari M, van Rhee F, Meissner T, Goldschmidt H, Hemminki K, Houlston R, Barlogie B, Davies FE, Morgan GJ, Weinhold N.

Blood. 2017 Jul 6;130(1):30-34. doi: 10.1182/blood-2017-03-774422. Epub 2017 Apr 21.

PMID:
28432222
13.

Immunologic approaches for the treatment of multiple myeloma.

Rasche L, Weinhold N, Morgan GJ, van Rhee F, Davies FE.

Cancer Treat Rev. 2017 Apr;55:190-199. doi: 10.1016/j.ctrv.2017.03.010. Epub 2017 Apr 6. Review.

14.

Clinical characteristics and prognostic factors in multiple myeloma patients with light chain deposition disease.

Mohan M, Buros A, Mathur P, Gokden N, Singh M, Susanibar S, Jo Kamimoto J, Hoque S, Radhakrishnan M, Matin A, Davis C, Grazziutti M, Thanendrarajan S, van Rhee F, Zangari M, Davies F, Morgan G, Epstein J, Barlogie B, Schinke C.

Am J Hematol. 2017 Aug;92(8):739-745. doi: 10.1002/ajh.24756. Epub 2017 Jun 1.

PMID:
28383130
15.

Extensive Remineralization of Large Pelvic Lytic Lesions Following Total Therapy Treatment in Patients With Multiple Myeloma.

Mohan M, Samant RS, Yoon D, Buros AF, Branca A, Montgomery CO, Nicholas R, Suva LJ, Morello R, Thanendrarajan S, Schinke C, Yaccoby S, van Rhee F, Davies FE, Morgan GJ, Zangari M.

J Bone Miner Res. 2017 Jun;32(6):1261-1266. doi: 10.1002/jbmr.3111. Epub 2017 Mar 27.

PMID:
28240368
16.

Bi-allelic inactivation is more prevalent at relapse in multiple myeloma, identifying RB1 as an independent prognostic marker.

Chavan SS, He J, Tytarenko R, Deshpande S, Patel P, Bailey M, Stein CK, Stephens O, Weinhold N, Petty N, Steward D, Rasche L, Bauer M, Ashby C, Peterson E, Ali S, Ross J, Miller VA, Stephens P, Thanendrarajan S, Schinke C, Zangari M, van Rhee F, Barlogie B, Mughal TI, Davies FE, Morgan GJ, Walker BA.

Blood Cancer J. 2017 Feb 24;7(2):e535. doi: 10.1038/bcj.2017.12.

17.

International, evidence-based consensus diagnostic criteria for HHV-8-negative/idiopathic multicentric Castleman disease.

Fajgenbaum DC, Uldrick TS, Bagg A, Frank D, Wu D, Srkalovic G, Simpson D, Liu AY, Menke D, Chandrakasan S, Lechowicz MJ, Wong RS, Pierson S, Paessler M, Rossi JF, Ide M, Ruth J, Croglio M, Suarez A, Krymskaya V, Chadburn A, Colleoni G, Nasta S, Jayanthan R, Nabel CS, Casper C, Dispenzieri A, Fosså A, Kelleher D, Kurzrock R, Voorhees P, Dogan A, Yoshizaki K, van Rhee F, Oksenhendler E, Jaffe ES, Elenitoba-Johnson KS, Lim MS.

Blood. 2017 Mar 23;129(12):1646-1657. doi: 10.1182/blood-2016-10-746933. Epub 2017 Jan 13.

18.

The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of hematologic malignancies: multiple myeloma, lymphoma, and acute leukemia.

Boyiadzis M, Bishop MR, Abonour R, Anderson KC, Ansell SM, Avigan D, Barbarotta L, Barrett AJ, Van Besien K, Bergsagel PL, Borrello I, Brody J, Brufsky J, Cairo M, Chari A, Cohen A, Cortes J, Forman SJ, Friedberg JW, Fuchs EJ, Gore SD, Jagannath S, Kahl BS, Kline J, Kochenderfer JN, Kwak LW, Levy R, de Lima M, Litzow MR, Mahindra A, Miller J, Munshi NC, Orlowski RZ, Pagel JM, Porter DL, Russell SJ, Schwartz K, Shipp MA, Siegel D, Stone RM, Tallman MS, Timmerman JM, Van Rhee F, Waller EK, Welsh A, Werner M, Wiernik PH, Dhodapkar MV.

J Immunother Cancer. 2016 Dec 20;4:90. doi: 10.1186/s40425-016-0188-z. eCollection 2016.

19.

Adverse Metaphase Cytogenetics Can Be Overcome by Adding Bortezomib and Thalidomide to Fractionated Melphalan Transplants.

Jethava YS, Mitchell A, Epstein J, Zangari M, Yaccoby S, Tian E, Waheed S, Khan R, Papanikolaou X, Grazziutti M, Cottler-Fox M, Petty N, Steward D, Panozzo S, Bailey C, Hoering A, Crowley J, Sawyer J, Morgan G, Barlogie B, van Rhee F.

Clin Cancer Res. 2017 Jun 1;23(11):2665-2672. doi: 10.1158/1078-0432.CCR-15-2620. Epub 2016 Nov 3.

PMID:
27810902
20.

Hyperhaploidy is a novel high-risk cytogenetic subgroup in multiple myeloma.

Sawyer JR, Tian E, Shaughnessy JD Jr, Epstein J, Swanson CM, Stangeby C, Hale CL, Parr L, Lynn M, Sammartino G, Lukacs JL, Stein C, Bailey C, Zangari M, Davies FE, Van Rhee F, Barlogie B, Morgan GJ.

Leukemia. 2017 Mar;31(3):637-644. doi: 10.1038/leu.2016.253. Epub 2016 Oct 3.

PMID:
27694925

Supplemental Content

Loading ...
Support Center